Clinical Trial Update: Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH) [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating clazosentan to prevent cerebral vasospasm after aneurysmal subarachnoid hemorrhage has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aneurysmal Subarachnoid Hemorrhage

Drugs mentioned

• Clazosentan (clazosentan)

Snippet

Sponsor: Idorsia Pharmaceuticals Ltd. | Conditions: Aneurysmal Subarachnoid Hemorrhage | Phase 2 | Status: COMPLETED